Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205921684> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W3205921684 abstract "<h3>Introduction/Background*</h3> As there are only a few therapy options for advanced or recurrent leiomyosarcoma (LMS) and Carcinosarcomas (CS), new effective drug combinations with an acceptable toxicity profile are urgently needed. Pazopanib is an orally available second-generation multi targeted tyrosine kinase inhibitor (TKI), targeting among others VEGFR, PFGG and c-kitand is approved in soft tissue sarcomas. A phase I study evaluated the combination of pazopanib and gemcitabine and showed an acceptable toxicity profile. We aim to test the activity of the combination therapy in patients with LMS in a randomized setting and to describe the activity in CS. <h3>Methodology</h3> The PazoDoble study is a prospective, randomized, open-label, multicentre phase II trial. Patients with relapsed or metastatic uterine LMS or uterine CS are eligible for participation. LMS are randomised in a 1:1 fashion into two treatment arms. A: pazopanib 800 mg p.o./d plus gemcitabine 1000mg/m2 i.v. over 30 min d1 und d8 q3w or B: pazopanib 800 mg p.o./d. Uterine CS will be enrolled only in Arm A. Duration of therapy will be maximum 18 months or until progression, death or unacceptable toxicity. Primary Endpoints are the six month PFS and clinical progression; Secondary endpoints are the objective response rate, duration of response, time to progression, OS, toxicity and tolerability and quality of life. A previousatment with doxorubicin or any contraindications against doxorubicin and an ECOG of 0 or 1 are mandatory. Clinical and imaging follow-up are scheduled every three month until disease progression or death. Enrolment was started in October 2019 at nine sites. Until now, 12 Patients are enrolled (5 CS and 7 LMS). We aim to include 87 patients with LMS and 20 with CS. The primary endpoint will be analysed as the ratio of the number of patients showing no progress after 6 month divided by the number of evaluable patients. A drop-out rate of 5% was assumed. <h3>Result(s)*</h3> <h3>Conclusion*</h3> In the clinical setting of advanced and recurrent LMS and CS there are no well-evaluated therapies available. This trial is clinically highly relevant and offers opportunity for patients to receive promising therapy." @default.
- W3205921684 created "2021-10-25" @default.
- W3205921684 creator A5002555374 @default.
- W3205921684 creator A5008644034 @default.
- W3205921684 creator A5038723818 @default.
- W3205921684 creator A5048170384 @default.
- W3205921684 creator A5050467390 @default.
- W3205921684 creator A5056845538 @default.
- W3205921684 creator A5071559843 @default.
- W3205921684 creator A5073058678 @default.
- W3205921684 creator A5078567055 @default.
- W3205921684 creator A5088082888 @default.
- W3205921684 date "2021-10-01" @default.
- W3205921684 modified "2023-10-02" @default.
- W3205921684 title "169 PazoDoble – Pazopanib vs. Pazopanib plus Gemcitabine in relapsed or metastatic uterine leiomyosarcomas or uterine carcinosacomas" @default.
- W3205921684 doi "https://doi.org/10.1136/ijgc-2021-esgo.253" @default.
- W3205921684 hasPublicationYear "2021" @default.
- W3205921684 type Work @default.
- W3205921684 sameAs 3205921684 @default.
- W3205921684 citedByCount "0" @default.
- W3205921684 crossrefType "proceedings-article" @default.
- W3205921684 hasAuthorship W3205921684A5002555374 @default.
- W3205921684 hasAuthorship W3205921684A5008644034 @default.
- W3205921684 hasAuthorship W3205921684A5038723818 @default.
- W3205921684 hasAuthorship W3205921684A5048170384 @default.
- W3205921684 hasAuthorship W3205921684A5050467390 @default.
- W3205921684 hasAuthorship W3205921684A5056845538 @default.
- W3205921684 hasAuthorship W3205921684A5071559843 @default.
- W3205921684 hasAuthorship W3205921684A5073058678 @default.
- W3205921684 hasAuthorship W3205921684A5078567055 @default.
- W3205921684 hasAuthorship W3205921684A5088082888 @default.
- W3205921684 hasBestOaLocation W32059216841 @default.
- W3205921684 hasConcept C121608353 @default.
- W3205921684 hasConcept C126322002 @default.
- W3205921684 hasConcept C126894567 @default.
- W3205921684 hasConcept C143998085 @default.
- W3205921684 hasConcept C197934379 @default.
- W3205921684 hasConcept C203092338 @default.
- W3205921684 hasConcept C2776694085 @default.
- W3205921684 hasConcept C2778375690 @default.
- W3205921684 hasConcept C2778439243 @default.
- W3205921684 hasConcept C2778820342 @default.
- W3205921684 hasConcept C2779490328 @default.
- W3205921684 hasConcept C2780258809 @default.
- W3205921684 hasConcept C2780739268 @default.
- W3205921684 hasConcept C29730261 @default.
- W3205921684 hasConcept C31760486 @default.
- W3205921684 hasConcept C535046627 @default.
- W3205921684 hasConcept C71924100 @default.
- W3205921684 hasConceptScore W3205921684C121608353 @default.
- W3205921684 hasConceptScore W3205921684C126322002 @default.
- W3205921684 hasConceptScore W3205921684C126894567 @default.
- W3205921684 hasConceptScore W3205921684C143998085 @default.
- W3205921684 hasConceptScore W3205921684C197934379 @default.
- W3205921684 hasConceptScore W3205921684C203092338 @default.
- W3205921684 hasConceptScore W3205921684C2776694085 @default.
- W3205921684 hasConceptScore W3205921684C2778375690 @default.
- W3205921684 hasConceptScore W3205921684C2778439243 @default.
- W3205921684 hasConceptScore W3205921684C2778820342 @default.
- W3205921684 hasConceptScore W3205921684C2779490328 @default.
- W3205921684 hasConceptScore W3205921684C2780258809 @default.
- W3205921684 hasConceptScore W3205921684C2780739268 @default.
- W3205921684 hasConceptScore W3205921684C29730261 @default.
- W3205921684 hasConceptScore W3205921684C31760486 @default.
- W3205921684 hasConceptScore W3205921684C535046627 @default.
- W3205921684 hasConceptScore W3205921684C71924100 @default.
- W3205921684 hasLocation W32059216841 @default.
- W3205921684 hasOpenAccess W3205921684 @default.
- W3205921684 hasPrimaryLocation W32059216841 @default.
- W3205921684 hasRelatedWork W18214132 @default.
- W3205921684 hasRelatedWork W18275474 @default.
- W3205921684 hasRelatedWork W1852032 @default.
- W3205921684 hasRelatedWork W1911331 @default.
- W3205921684 hasRelatedWork W3494926 @default.
- W3205921684 hasRelatedWork W4429043 @default.
- W3205921684 hasRelatedWork W5038423 @default.
- W3205921684 hasRelatedWork W5798067 @default.
- W3205921684 hasRelatedWork W9134849 @default.
- W3205921684 hasRelatedWork W17932051 @default.
- W3205921684 isParatext "false" @default.
- W3205921684 isRetracted "false" @default.
- W3205921684 magId "3205921684" @default.
- W3205921684 workType "article" @default.